Monte Rosa Therapeutics, Inc. (GLUE)

NASDAQ: GLUE · IEX Real-Time Price · USD

4.260

-0.130 (-2.96%)

At close: Jul 19, 2024, 4:00 PM

4.250

-0.010 (-0.23%)

Pre-market: Jul 22, 2024, 6:13 AM EDT

Monte Rosa Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	1.06	0	0	0	0	0
Gross Profit	1.06	0	0	0	0	0
Selling, General & Admin	33.52	32.04	27.32	15.73	4.01	0.64
Research & Development	111.54	111.27	85.06	57.16	24.01	7.35
Operating Expenses	145.06	143.31	112.38	72.88	28.01	7.99
Operating Income	-144	-143.31	-112.38	-72.88	-28.01	-7.99
Interest Expense / Income	0	0	0	0	0	-0
Other Expense / Income	-9.14	-8.3	-3.88	1.08	7.87	-0.25
Pretax Income	-134.86	-135.01	-108.5	-73.96	-35.88	-7.74
Income Tax	0.42	0.34	0	0	0	0
Net Income	-135.28	-135.35	-108.5	-73.96	-35.88	-7.74
Shares Outstanding (Basic)	60	51	47	25	2	5
Shares Outstanding (Diluted)	60	51	47	25	2	5
Shares Change	21.90%	8.83%	88.91%	1548.09%	-69.66%	-
EPS (Basic)	-2.51	-2.63	-2.30	-2.96	-23.65	-1.55
EPS (Diluted)	-2.51	-2.63	-2.30	-2.96	-23.65	-1.55
Free Cash Flow	-69.74	-62.78	-105.27	-69.02	-26.44	-7.56
Free Cash Flow Per Share	-1.16	-1.22	-2.23	-2.76	-17.43	-1.51
Gross Margin	100.00%	-	-	-	-	-
Operating Margin	-13533.74%	-	-	-	-	-
Profit Margin	-12714.47%	-	-	-	-	-
Free Cash Flow Margin	-6554.79%	-	-	-	-	-
EBITDA	-127.89	-128.79	-99.94	-71.83	-35.34	-7.67
EBITDA Margin	-12020.02%	-	-	-	-	-
Depreciation & Amortization	6.97	6.22	8.56	2.13	0.54	0.07
EBIT	-134.86	-135.01	-108.5	-73.96	-35.88	-7.74
EBIT Margin	-12674.91%	-	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).